Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 6
- Registration Number
- NCT00863850
- Locations
- 🇳🇱
Please Call For Information, Amsterdam, Netherlands
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- John Grecula
- Target Recruit Count
- 18
- Registration Number
- NCT00837928
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2018-04-17
- Target Recruit Count
- 11
- Registration Number
- NCT00834678
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Pharmatech
- Target Recruit Count
- 61
- Registration Number
- NCT00831597
- Locations
- 🇺🇸
Pharmatech Oncology Study Site, Richardson, Texas, United States
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00825149
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 45
- Registration Number
- NCT00823797
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Bendamustine in Acute Leukemia and MDS
- Conditions
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00790855
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 564
- Registration Number
- NCT00769522
- Locations
- 🇩🇪
Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany
Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- University of Kentucky
- Registration Number
- NCT00758693
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-08-25
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 39
- Registration Number
- NCT00740415
- Locations
- 🇫🇷
CHU de Grenoble - Hopital Michallon, Grenoble, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.